Therefore, through the data obtained, it can be concluded that it is safe to indicate both CPO and MRCP in cases suspected of choledocholithiasis through the initial clinical, laboratory and ultrasound, since the two methods are concordant in their results. The gene discussed is CPO; the disease is choledocholithiasis.